Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
July 03, 2024 04:00 ET
|
Pneumagen Ltd
Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of NeumifilNew preclinical...
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
May 23, 2024 07:00 ET
|
Pneumagen Ltd
Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
May 02, 2024 07:00 ET
|
Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
April 30, 2024 10:00 ET
|
RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board
April 25, 2024 10:00 ET
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce the addition of Jane Wright-Mitchell, Pharm.D., J.D. to the RS BioTherapeutics Business Advisory Board.
Global Interventional Pulmonology Market Analysis Report 2024-2028: Robotic Bronchoscopy is Emerging as a Game Changer in the $5+ Billion Industry
April 16, 2024 07:32 ET
|
Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Pulmonology Market: Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ...
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
March 18, 2024 11:30 ET
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit